Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation (2016 - 2025)

Historic Accumulated Depreciation for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $56.4 million.

  • Seres Therapeutics' Accumulated Depreciation rose 805.6% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year increase of 805.6%. This contributed to the annual value of $53.2 million for FY2024, which is 839.07% up from last year.
  • Seres Therapeutics' Accumulated Depreciation amounted to $56.4 million in Q3 2025, which was up 805.6% from $55.3 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Accumulated Depreciation high stood at $56.4 million for Q3 2025, and its period low was $35.8 million during Q1 2021.
  • Its 5-year average for Accumulated Depreciation is $47.3 million, with a median of $48.0 million in 2023.
  • In the last 5 years, Seres Therapeutics' Accumulated Depreciation surged by 2116.5% in 2021 and then skyrocketed by 281.51% in 2025.
  • Quarter analysis of 5 years shows Seres Therapeutics' Accumulated Depreciation stood at $40.3 million in 2021, then rose by 11.85% to $45.0 million in 2022, then increased by 8.97% to $49.1 million in 2023, then grew by 8.39% to $53.2 million in 2024, then rose by 5.98% to $56.4 million in 2025.
  • Its Accumulated Depreciation stands at $56.4 million for Q3 2025, versus $55.3 million for Q2 2025 and $54.3 million for Q1 2025.